Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells

References

• Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR. (2011). Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med, 52, 1970–1978.
   PubMed Web of Science ®Google Scholar
• Accardo A, Tesauro D, Aloj L, Tarallo L, Arra C, Mangiapia G, Vaccaro M, Pedone C, Paduano L, Morelli G. (2008). Peptide-containing aggregates as selective nanocarriers for therapeutics. ChemMedChem, 3, 594–602.
   PubMed Web of Science ®Google Scholar
• Accardo A, Mansi R, Morisco A, Mangiapia G, Paduano L, Tesauro D, Radulescu A, Aurilio M, Aloj L, Arra C, Morelli G. (2010). Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol Biosyst, 6, 878–887.
   PubMed Web of Science ®Google Scholar
• Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G. (2012). Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent. Int J Nanomedicine, 7, 2007–2017.
   PubMed Web of Science ®Google Scholar
• Battey JF, Way JM, Corjay MH, Shapira H, Kusano K, Harkins R, Wu JM, Slattery T, Mann E, Feldman RI. (1991). Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA, 88, 395–399.
   PubMed Web of Science ®Google Scholar
• Chan KY, Vermeersch S, de Hoon J, Villalón CM, Maassenvandenbrink A. (2011). Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. Pharmacol Ther, 129, 332–351.
   PubMed Web of Science ®Google Scholar
• Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, Upendran A, Kulkarni RR, Kan P, Fent GM, Casteel SW, Smith CJ, Boote E, Robertson JD, Cutler C, Lever JR, Katti KV, Kannan R. (2010). Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci USA, 107, 8760–8765.
   PubMed Web of Science ®Google Scholar
• Chang WC, White PD. (2000). Fmoc solid phase peptide synthesis. Oxford, UK: Oxford Univ Press.
   Google Scholar
• Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF. (1993). BRS-3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem, 268, 5979–5984.
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Waser B, Reubi JC. (2007). Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol, 29, 421–433.
   PubMedGoogle Scholar
• Gugger M, Reubi JC. (1999). Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol, 155, 2067–2076.
   PubMed Web of Science ®Google Scholar
• Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A. (2008). Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem, 19, 1871–1879.
   PubMed Web of Science ®Google Scholar
• Hosta-Rigau L, Olmedo I, Arbiol J, Cruz LJ, Kogan MJ, Albericio F. (2010). Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem, 21, 1070–1078.
   PubMed Web of Science ®Google Scholar
• Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, Sohn MH. (2010). Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res, 27, 712–721.
   PubMed Web of Science ®Google Scholar
• Llinares M, Devin C, Chaloin O, Azay J, Noel-Artis AM, Bernad N, Fehrentz JA, Martinez J. (1999). Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res, 53, 275–283.
   PubMedGoogle Scholar
• Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR. (2009). Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res, 15, 5240–5249.
   PubMed Web of Science ®Google Scholar
• Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR. (2011). Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging, 38, 97–107.
   PubMed Web of Science ®Google Scholar
• Markwalder R, Reubi JC. (1999). Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res, 59, 1152–1159.
   PubMed Web of Science ®Google Scholar
• Martin AL, Hickey JL, Ablack AL, Lewis JD, Luyt LG, Gillies ER. (2009). Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanopart Res, 12, 1599–1608.
   PubMed Web of Science ®Google Scholar
• Mendoza-Sánchez AN, Ferro-Flores G, Ocampo-García BE, Morales-Avila E, de M Ramírez F, De León-Rodríguez LM, Santos-Cuevas CL, Medina LA, Rojas-Calderón EL, Camacho-López MA. (2010). Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. J Biomed Nanotechnol, 6, 375–384.
   PubMed Web of Science ®Google Scholar
• Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT, Spindel ER. (1995). Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: Identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA, 92, 6205–6209.
   PubMed Web of Science ®Google Scholar
• Parry JJ, Kelly TS, Andrews R, Rogers BE. (2007). In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem, 18, 1110–1117.
   PubMed Web of Science ®Google Scholar
• Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ. (2003). MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem, 14, 756–763.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Dietrich C. (2004). Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces. J Am Chem Soc, 116, 8485–8491.
   Google Scholar
• Smith CJ, Volkert WA, Hoffman TJ. (2005). Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol, 32, 733–740.
   PubMed Web of Science ®Google Scholar
• Stewart JC. (1980). Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem, 104, 10–14.
   PubMed Web of Science ®Google Scholar
• Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R, Battery J. (1991). cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron, 6, 421–430.
   PubMed Web of Science ®Google Scholar
• Zhu YF, Chen C. (2004). Recent advances in small molecule gonadotrophin-releasing hormone receptor antagonists. Expert Opin Ther Pat, 14, 187–199.
   Web of Science ®Google Scholar